Statements (66)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:biotechnology
|
| gptkbp:administered_by |
Adults
Healthcare professionals Injection Clinical settings Outpatient settings Patients with chronic conditions Infusion centers Patients with autoimmune disorders Patients with severe conditions |
| gptkbp:clinical_trial |
gptkb:Judge
|
| gptkbp:developed_by |
gptkb:biotechnology
Pharmaceutical companies |
| gptkbp:has_lower_cost_than |
Infliximab
|
| gptkbp:has_similar_efficacy_to |
Infliximab
|
| https://www.w3.org/2000/01/rdf-schema#label |
Biosimilar to Infliximab
|
| gptkbp:is_approved_for |
gptkb:Crohn's_disease
gptkb:Ulcerative_colitis Rheumatoid arthritis |
| gptkbp:is_available_in |
Multiple countries
|
| gptkbp:is_compared_to |
Reference product
|
| gptkbp:is_considered |
Cost-effective option
Alternative treatment Effective treatment option First-line therapy Second-line therapy Substitutable for Infliximab Therapeutic alternative Therapeutic equivalent |
| gptkbp:is_evaluated_by |
Safety
Quality of life Cost-effectiveness Immunogenicity Patient outcomes Patient safety Efficacy Therapeutic outcomes Long-term effects |
| gptkbp:is_part_of |
gptkb:health_services
Clinical trials Healthcare policies Treatment guidelines Biopharmaceutical industry Pharmaceutical market Biologics category Treatment regimen |
| gptkbp:is_regulated_by |
gptkb:FDA
|
| gptkbp:is_similar_to |
Infliximab
|
| gptkbp:is_subject_to |
Patent laws
Regulatory approval process |
| gptkbp:is_used_for |
Chronic inflammatory conditions
|
| gptkbp:is_used_in |
Cancer treatment
Gastroenterology Rheumatology Infusion therapy Dermatology Chronic disease management Ankylosing spondylitis Pediatric patients Psoriasis treatment Immune-mediated diseases |
| gptkbp:marketed_as |
Various manufacturers
Different brand names |
| gptkbp:serves |
Autoimmune diseases
|
| gptkbp:bfsParent |
gptkb:Merck_Biosimilars
|
| gptkbp:bfsLayer |
6
|